Work

A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial.

Year: 2011

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2011.29.15_suppl.5502

Authors: J. A. Sosa, R. Elisei, B. Jarzab, C. S. Bal, H. Koussis, A. W. Gramza, R. Ben-Yosef, B. J. Gitlitz, B. Haugen, S. M. Karandikar, F. R. Khuri, L. F. Licitra, S. C. Remick, S. Marur, C. Lu, F. G. Ondrey, S. Lu, J. Balkissoon

Language: English

Topic: Thyroid Cancer Diagnosis and Treatment

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1894790766

Cites:

Cited by: 40

Related to: 10